PhI­II fail­ure trig­gers lay­offs, spend­ing cuts and warn­ing of 'dis­so­lu­tion' for sin­gle-mind­ed biotech

When you are stak­ing your whole busi­ness on a make-or-break Phase III tri­al, fail­ure can be dev­as­tat­ing.

Just ask Neu­rana Phar­ma­ceu­ti­cals.

The lit­tle San Diego …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER